Supplementary Table 1: The antibodies used in this study

Antigen	*Antibody*	*Application*	*Dilution*	*Source*
20S Proteasome	PW 8155	IF	1:2000	Biomol
alpha-tubulin	T9026	IB	1:5000	Sigma-Aldrich
α-syn (human)	Syn211	IB	1:2000	(Bruening et al, 2000)
α-syn (mouse)	mSyn-1	IB	1:500	(Vopicelli-Daley et al., 2011)
CD-63	CD-63	IF	1:500	(Abache et al, 2007)
GFP	sc-9996	IB	1:500	Santa Cruz
Lamp1 (human)	H4A3	IF,IB	1:1000, 1:1000	BD biosciences
Lamp1 (mouse)	1D4B	IF	1:500	Developmental Studies Hybridoma
LC3	PM036	IF, IB	1:2000, 1:500	MBL
myc	9E10	IF	1:2000	DHSB
p62 (human)	610832	IF, IB	1:2000, 1:1000	BD Transduction
p62 (mouse)	2C11	IF, IB	1:1000, 1:1000	Abnova
p-α-syn	81a	IF, IB	1:8000, 1:1000	(Waxman & Giasson, 2008)
p-α-syn	p-α-syn 6.2	IF	1:1000	(Luk et al, 2012)
Tuj-1	MMS-435P	IB	1:5000	Covance
Ubiquitin	Ub1B4	IB, IF	1:1000, 1:1000	(Sampathu et al, 2006)

Supplementary Information, Tanik et al.

Supplementary Table 2: Quantification results that are used for statistical analyses

Figure	*Data Set*	*Mean*	*SEM*	*n*	*Figure*	*Data Set*	*Mean*	*SEM*	*n*	*Figure*	*Data Set*	*Mean*	*SEM*	*n*	*Figure*	*Data Set*	*Mean*	*SEM*	*n*
2B	PBS	6.3	4.7	3	3C	0h PBS	103.1	2.7	4		TX (KO)	91.7	8.4	5		Starve	2.2	0.3	3
	0h	18.4	22.3	3		24h PBS	126.6	12.9	4		SDS (wt)	163.5	27.7	5	11D	Comp	0.7	0.1	2
	(-)	100.0	N/A*	3		48h PBS	73.4	6.0	4		SDS (KO)	116.1	10.1	5		Rap	0.6	0.0	2
	3-MA	91.1	28.1	3		72h PBS	29.9	3.6	4	7C	(-) PBS	18.8	4.5	4		Starve	0.5	0.1	2
	Rap	166.5	33.7	3		0h Pff	114.7	6.0	4		3-MA PBS	83.9	15.8	4					
2D	(-) PBS	2.2	1.1	3		24h Pff	120.0	20.6	4		Rap PBS	14.4	3.9	4					
	Rap PBS	5.3	0.7	3		48h Pff	125.4	17.1	4		(-) Pff	45.8	6.4	4					
	Cq (-) PBS	11.6	4.6	3		72h Pff	111.8	18.5	4		3-MA Pff	100.0	N/A*	4					
	Cq Rap PBS	11.3	3.0	3	4B	p62 (α-syn)	342.0	37.5	7		Rap Pff	59.2	3.5	4					
	(-) Pff	100.0	N/A*	3		p62 (naïve)	103.0	9.8	3	7E	α-syn	295.0	98.4	4					
	Rap Pff	128.2	24.2	3		LC3 (α-syn)	254.8	29.1	5		naïve	82.2	12.1	4					
	Cq (-) Pff	87.8	12.4	3		LC3 (naïve)	99.5	32.7	3	8B	(-) PBS	7.9	2.4	4					
	Cq Rap Pff	122.3	21.0	3	4D	TX (α-syn)	126.2	14.6	8		(Cq) PBS	137.9	4.4	4					
2F	(-) PBS	12.1	3.7	3		TX (naïve)	103.0	24.9	4		(-) Pff	24.6	5.4	4					
	Atg4b PBS	10.2	3.7	3		SDS (α-syn)	286.7	43.2	5		(Cq) Pff	139.5	9.3	4					
	Cq (-) PBS	8.5	3.9	3		SDS (naïve)	114.6	30.6	3	8D	0h PBS	100.0	N/A*	4					
	Cq Atg4b PBS	17.3	3.6	3	5D	0h	15.2	9.0	3		24h PBS	52.0	7.8	4					
	(-) Pff	100.0	N/A*	3		(-)	100.0	N/A*	3		48h PBS	3.6	5.0	4					
	Atg4b Pff	85.4	14.0	3		Starve	129.9	23.8	3		72h PBS	2.7	1.6	3					
	Cq (-) Pff	77.3	11.0	3		3MA	87.9	22.6	3		72h (-) PBS	2.7	1.2	3					
	Cq Atg4b Pff	73.6	6.0	3	5F	10d-TX PBS	77.0	11.9	3		0h Pff	100.0	N/A*	4					
3B	0h-TX PBS	100.0	N/A*	4		14d-TX PBS	78.6	24.3	3		24h Pff	102.0	16.5	4					
	24h-TX PBS	125.7	6.3	4		17d-TX PBS	52.8	15.8	3		48h Pff	32.5	2.9	4					
	48h-TX PBS	72.6	2.8	4		10d-SDS PBS	0.0	0.0	3		72h Pff	20.2	3.6	3					
	72h-TX PBS	29.0	1.9	4		14d-SDS PBS	0.0	0.0	3		72h (-) Pff	7.0	0.2	3					
	0h-SDS PBS	3.1	2.7	4		17d-SDS PBS	0.0	0.0	3	9A	(-) PBS	4.5	0.7	3					
	24h-SDS PBS	0.9	0.8	4		10d-TX Pff	43.1	14.0	3		(-) Pff	17.0	0.3	3					
	48h-SDS PBS	0.8	0.7	4		14d-TX Pff	20.8	8.8	3		LI PBS	14.4	0.5	3					
	72h-SDS PBS	1.0	0.9	4		17d-TX Pff	25.5	6.9	3		LI Pff	16.8	0.8	4					
	0h-TX Pff	100.0	N/A*	4		10d-SDS Pff	47.5	14.0	3	11A	PBS naïve	10.4	0.0	2					
	24h-TX Pff	54.9	5.0	4		14d-SDS Pff	137.2	40.1	3		Pff naïve	11.4	0.7	2					
	48h-TX Pff	20.7	6.4	4		17d-SDS Pff	147.3	28.8	3		PBS α-syn	11.8	0.2	2					
	72h-TX Pff	13.3	2.0	4	6B	p62 (wt)	397.2	88.6	5		Pff α-syn	29.8	5.4	2					
	0h-SDS Pff	18.8	3.6	4		p62 (KO)	109.1	7.0	5	11B	Comp	0.9	0.0	4					
	24h-SDS Pff	75.9	7.8	4		LC3 (wt)	210.7	32.3	4		Rap	0.6	0.0	4					
	48h-SDS Pff	109.0	15.6	4		LC3 (KO)	107.0	15.2	3		Starve	0.7	0.0	4					
	72h-SDS Pff	129.0	5.5	4	6D	TX (wt)	107.0	4.7	5	11C	Comp	1.2	0.3	3					

*SEM Not applicable (N/A) due to normalization process.

Supplementary References

Abache T, Le Naour F, Planchon S, Harper F, Boucheix C, Rubinstein E (2007) The transferrin receptor and the tetraspanin web molecules CD9, CD81, and CD9P-1 are differentially sorted into exosomes after TPA treatment of K562 cells. *Journal of cellular biochemistry* **102:** 650-664

Bruening W, Giasson BI, Klein-Szanto AJ, Lee VMY, Trojanowski JQ, Godwin AK (2000) Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. *Cancer* **88:** 2154-2163

Fujita N, Hayashi-Nishino M, Fukumoto H, Omori H, Yamamoto A, Noda T, Yoshimori T (2008) An Atg4B mutant hampers the lipidation of LC3 paralogues and causes defects in autophagosome closure. *Molecular biology of the cell* **19:** 4651-4659

Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VMY(2012) Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. *The Journal of experimental medicine* **209:** 975-986

Sampathu DM, Neumann M, Kwong LK, Chou TT, Micsenyi M, Truax A, Bruce J, Grossman M, Trojanowski JQ, Lee VMY (2006) Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. *Am J Pathol* **169:** 1343-1352

Sherer NM, Lehmann MJ, Jimenez-Soto LF, Ingmundson A, Horner SM, Cicchetti G, Allen PG, Pypaert M, Cunningham JM, Mothes W (2003) Visualization of retroviral replication in living cells reveals budding into multivesicular bodies. *Traffic* **4:** 785-801

Waxman EA, Giasson BI (2008) Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. *Journal of neuropathology and experimental neurology* **67:** 402-416